Artios Pharma Wins 2018 Lifestars EU Private Finance Raise of the Year Award

Cambridge, UK, 14 November 2018. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, is pleased to announce that it has won the 2018 Lifestars “>£30m EU Private Finance Raise of the Year” Award.

14 November 2018
Read more
Artios Pharma’s £65m Series B To Spur Development Of DDR Cancer Therapies

LSX article on Artios following our recent £65 million Series B fundraise and having being shortlisted in the EU Private Finance Raise of the Year (>£30m) category and also the EU Private Company of the Year category at this year’s Lifestars Awards 2018. This follows a double win at LSX’s Biotech and Money Awards 2017. […]

23 October 2018
Read more
Vacancy: Senior Scientist: Biochemistry and Screening

With an expanding small molecule drug discovery portfolio Artios Pharma is recruiting for a biochemistry and screening scientist. This is an excellent opportunity to join a world class research team in a dynamic, small Biotech company based south of Cambridge, UK. Artios is focused on identifying and developing cancer treatments by exploiting novel targets within […]

4 October 2018
Read more
Artios Pharma Announces $84 million (£65 million) Series B Financing

Financing Round Led by New Investors Andera Partners and LSP Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion of a $84 million (£65 million) Series B financing following high interest from investors.

10 August 2018
Read more
Artios attending the BIO 2018 conference in Boston, USA on June 4-7, 2018

Artios will be attending the BIO 2018 conference in Boston, USA on June 4-7, 2018. Artios is leading the development of first-in-class next-generation DNA Damage Response (DDR) programmes, including Pol theta. Please contact us through the conference partnering system if you would like to meet with Artios. No service providers please.

29 May 2018
Read more
Artios exercises option to in-license potential first-in-class nuclease development programme

Cambridge, UK, 5 March 2018. Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces that it has exercised its option to in-license the first nuclease drug development programme under its research collaboration and option agreement with Masaryk University in the Czech Republic. The collaboration was formed in […]

5 March 2018
Read more
Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

  Industry leader who brings over 35 years of experience in developing successful pharmaceutical companies Cambridge UK, 26 February 2018 – Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Pierre Legault MBA, CA, CPA as Chairman of its Board of Directors, with immediate […]

26 February 2018
Read more
Interview with Artios’ CEO following Biotech and Money’s Awards 2017

Artios Pharma scooped two awards at the Biotech and Money Awards 2017. The DNA Damage Response company was named winner in the UK Life Science Young Company of the Year (1-3 years old) category and the UK Private Finance Raise of the Year (≤£25 million) category. Biotech and Money spoke to Artios Pharma’s Chief Executive […]

16 November 2017
Read more
Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017

Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.

15 September 2017
Read more
Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

Cambridge, UK, 4 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Dr Graeme Smith as its Chief Scientific Officer (CSO). 

4 September 2017
Read more
Artios signs research collaboration with Masaryk University to develop novel cancer treatments targeting DNA nucleases in the DDR

Cambridge, UK, 12 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA nucleases involved in the DDR.

12 June 2017
Read more
Artios announces formation of world-leading Scientific Advisory Board

Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr […]

8 June 2017
Read more
Artios Strengthens Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Artios Pharma Ltd (“Artios” or “the Company”) Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy  Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team […]

2 November 2016
Read more
Artios attending the AACR conference “DNA Repair: Tumor Development and Therapeutic Response” in Montreal, Canada on Nov 2-5

Niall Martin, CEO and Nick Staples, CBO from Artios will be attending the AACR conference “DNA Repair: Tumor Development and Therapeutic Response” in Montreal, Canada on Nov 2-5, 2016.  Artios is actively looking to expand its development pipeline with novel DDR programmes and collaborations. Please contact us at  info@artiospharma.com or call on +44 (0)1223 804180 if you would like to meet […]

31 October 2016
Read more
Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies

Artios Pharma Ltd (“Artios” or “the Company”) $33.2 Million Series A Financing from SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures to fund development of a DDR focussed pipeline Cambridge, UK, 21 September 2016. Artios Pharma Ltd., a new private company focussed […]

21 September 2016
Read more